Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC)

Capecitabine use in geriatric oncology: An analysis of current safety, efficacy, and quality of life data

“…Beato et al [25] showed that treatment with single-agent capecitabine for first-line metastatic colorectal cancer significantly improves global health status (P = 0.035), physical functioning (P = 0.012), and defecation problems (P = 0.008) in females; constipation (P = 0.019) and sexual functioning (P = 0.013) in males; future perspective (female: P = 0.003; male: P = 0.006) and weight loss (female: P = 0.004; male: P = 0.013) in both sexes. However, no studies have reported specifically on the quality of life among elderly patients treated with capecitabine for metastatic colorectal cancer.…”

“…By virtue of its oral formulation and comparable efficacy, capecitabine may be particularly attractive for elderly cancer patients [23][24][25]. The NCCN, in fact, currently suggests capecitabine as an alternative to 5-FU, and lists it among preferred single agents for the initial treatment of metastatic breast cancer [14].…”